To compile the results of investigations conducted in 84 centers throughout Europe of the in vitro activity of meropenem and a standard set of comparators against some 12 000 Gram-positive, Gram-negative, aerobic and anaerobic bacteria.
available competitors, in many individual centers. Occasionally these data are published as national surveys but it is rare for larger data sets to be compiled and published.
With the wish to present a perspective of Europewide meropenem minimum inhibitory concentration (MIC) studies, we report on 84 sets of data. They were collected between 1988 and 1994 &om eight countries: France (lo), Germany (22), The Netherlands (4), Italy (14) , Spain (12), Sweden (l), Switzerland (2) and the UK (19) . The spectrum and potency of meropenem were compared with those of a standard set of comparator agents.
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In this study the core comparators against aerobes were imipenem, cefotaxime, cefiazidime, piperacillin, ciprofloxacin and gentamicin. Anaerobes were tested for susceptibility to imipenem, clindamycin and nietronidazole. Not reported here are the additional antibiotics that may have been included because of the type of bacteria examined and the particular antibiotic policies of an individual center. However, a further report [Greenhalgh and Edwards, this Supplement] contrasts the activity of meropenem with these other antibiotics and also newer agents such as cefepime, cefpirome and piperacillin/tazobactam, which were not available at the start of this multicenter evaluation.
The primary objective of this data presentation is to allow an evaluation of the activity of nieropenem and comparators across European countries.
MATERIALS AND METHODS

Study centers
The 84 centers, the chief investigator, the country, the year of the investigation and the categories of organisms tested (Gram-positive aerobes, nutritionally fastidious strains, Gram-negative aerobes, non-fermenters or anaerobes) are presented in Table 1 .
Bacterial isolates and test methods
Recent clinical isolates were used and their susceptibility to ineropenern and comparators assessed in the majority of centers as indicated in Table 2 . As none of the compounds tested was significantly active against methicillin-resistant staphylococci, Entevococrus jaeciurn and Stenotrophornonus maltophiliu, these organisms were excluded froin the results. Results were compiled into a computer database as individual MICs and analyzed. The few centers that used different agar or broth media produced results that fell within the spread of MICs recorded overall and were included. Evidence in the literature that medium and inoculuni do not significantly influence meropenem MIC results [l-31 validate these inclusions.
Quality control data
Quality control testing using reference strains was an integral part of this MIC study program. In general, meropenem and comparator drug MICs obtained using aerobic and anaerobic ATCC strains recommended by the National Committee for Clinical Laboratory Standards (NCCLS) produced acceptable quality control values. Ninety-five per cent (585/616) of meropenem results and 2387/2713 (88%) of comparator MICs fell within the proposed values for meropenem or within NCCLS-recommended guidelines. 1990  1990  1990  1991  1991  1990  1991  1990   1988  1989  1990  1990  1990  1990  1990  19VO  1990  1992  1992  1994   1988   1989  1989   1989  1987  1988  1988  1988  1988  1989  1989  1992  1993  1993  1992  1990  1991  1991  1992  1992  1992  1994   1987  1989  1988  1988  1991  1991  1991  1992  1993 
Antibiotics
Meropenem was supplied by Zeneca Pharmaceuticals; all other antibiotics were obtained from commercial sources.
RESULTS
Reproducibility of activity across Europe
The reproducibility of the measurement of the activity of meropenem across Europe, judged by MIC9os (mg/L) in the six countries performing most tests (France, Germany, The Netherlands, Italy, Spain, the UK) is shown in Table 3 . If MICsn had been used, the trends in the results given below would still have been valid (Zeneca, data on file). Evaluated by organism, the majority of meropenem results showed potent activity that was identical or within one or two doubling dilutions across countries; this was also the case for imipenem, with the exception of results against Pseudomonas aeruginosa, where MICm ranged from 4 mg/L to two results at 32 mg/L. Cefotaxime and ceftazidime showed uniformly good activity against few organisms, with variation being most obvious when tested against Enterobacter, Citrobacter, Serratia and, to some extent, Klebsiella species. As expected, cefotaxime was essentially inactive against l? aeruginosa but ceftazidime MIC9o results ranged from 8 to 64 mg/L. The results for piperacillin were either very poor or were variable, as were those for gentamicin. Ciprofloxacin exhibited potent and reproducible activity against Staphylococcus auveus, Haemophilus inzuenzae and Escherichia coli but among other Enterobacteriaceae there was at least one country with an MIC9o of 21 mg/L and the l? aeruginosa MICgo results ranged from 0.5 to 32 mg/L.
The carbapenems were exceptional in this assessment. However, they were differentiated from each other by the more uniform activity of meropenem against l? aeruginosa across countries. 
Reproducibility of the activity of meropenem across studies
Comparison of spectrum and potency
The data presented in Tables 5 (Gram-positive Meropenem and imipenem were the two most active compounds against Gram-positive aerobes, with imipenem being 2-4-fold more potent than meropenem against methicdlin-susceptible staphylococci, penicillin-resistant pneumococci and Enterococcurfaecafis (Table 5) . Cefotaxime and ceftazidime were often similar in (Table 6) . activity to imipenem but had higher MICs, notably with strains of the Citrobacter-Enterobacter-Serratia group. Piperacillin was less active still and many of the strains showed MIC9os 2 128 mg/L. Ciprofloxacin was often similar in potency to meropenem but ciprofloxacin-resistant strains were seen, notably amongst Serratia marcexens and Providencia stuartii. Gentamicin was often significantly less active ( Table 7) . The meropenem MIC90 for both P ueruginosa and Burkholderiu cepacia was 4 mg/L, while the results for imipenem against these organisms were 8 and 32 mg/L, respectively. Ciprofloxacin had an MIC90 of 1 mg/L against P aeruginosa but the results of 4 mg/L against Burkholderia cepacia was of questionable therapeutic value. Other comparators were less active. The two carbapenems exhibited sirmlar good activity (MICsos 5 4 mg/L) against Acinetobacter species but the other comparators did not provide uniform activity or were inactive (Table 8) .
Turner and Edwards: I n v i t r o a c t i v i t y of meropenem
Meropenem was the most active compound tested against all anaerobes (MICso 5 2 mg/L). Inlipenem was similar in activity against Gram-negative bacilli and anaerobic cocci but was often at least lbfold less potent than meropenem against the clostriha. The reference anti-anaerobe compounds, clindamycin and metronidazole, were less potent ( Table 9 ).
DISCUSSION
Given the wealth of published data, it is not surprising that, in common with other studies [2,4-181, results from some of them included here, the data presented show that meropenem possesses excellent activity against almost all clinically important bacteria, whether Gram-positive or -negative, or aerobes or anaerobes. Exceptions are methicillin-resistant staphylo-cocci, Enterococcus faecium or Stenotrophornonas rnaltophilia. However, the objective of this study was to assess reproducibility of activity across studies and countries, and in so doing it revealed interesting findings, particularly relating to the frequency with which bacterial resistance is now encountered. Meropenern and imipenem were the only compounds that exhbited uniformity of activity. However, if potential for resistance was considered, they could be differentiated by the more uniform activity of meropenem against l? aeruginosa.
The results for ceftazidime and cefotaxime, which often have an important role in the treatment of serious infection, showed significant problems of bacterial resistance, notably among Gram-negative aerobes. This may be explained by either overexpression of type I p-lactamase [19, 20] or, of greater concern, the harboring of the new TEM or SHV mutants that are transferable [21] . All established third-generation cephalosporins are unstable to these enzymes and the newer agents, cefepime and cefiirome, fail to resolve the problem satisfactorily [Z] .
Piperacillin MIC90s of 2 128 mg/L were commonplace among the Enterobacteriaceae, Pseudomonas and Acinetobacter species. While a piperacillin/tazobactam combination is now available, tazobactam will do little to protect against hydrolysis by type I p-lactamases when overexpressed [23] , and new TEM derivatives that hydrolyze P-lactamase inhibitors already exist [24] . Supporting data can be found in Greenhalgh and Edwards [this Supplement].
Compiled data showed that MIC90s (and indeed, MICsos) of gentamicin often approached or were above therapeutically useful values. Gentamicin has no activity against anaerobes, and resistance in aerobes is caused either by aminoglycoside-modifying enzymes, reduced permeability or ribosomal resistance [25] . While gentamicin provides a good example of aminoglycoside activity differences do occur with some of the other members of this class of antibiotics (e.g. tobramycin, n e t h c i n and amikacin). This is reviewed by Greenhalgh and Edwards (in this Supplement).
The trends towards elevated ciprofloxacin MICs for many species revealed by these data is confirmed in more recent studies and surveys [26, 27] . It is a considerable disappointment that 4-quinolone resistance is now an established fact.
Reports of resistance to clindamycin have been published [28] ; in this study, resistance was seen amongst Bacteroides, Clostridiurn and anaerobic cocci. Conversely, emergence of resistance to metronidazole is a rarity.
Of great concern is the rapid spread of penicillin resistance amongst Streptococcus pneumoniae. Resistance in this species to many chemically unrelated agents is frequently seen, and all p-lactam antibiotics show &minished susceptibility to some extent [29] ; Table 9 continued Clinical M i c r o b i o l o g y a n d Infection, Volume 3 S u p p l e m e n t 4
Prevotella oris (12) Prevotella buccae (24) Prevotella denticola (10) Porphyromonas asaccharolytica (45)
Fusobacterium nucleatum (68)
Willonella paruula (20) Eubactevium lentum (10) Propionibacterium acnes (25) Peptostreptococcus anaerobius (85) Overall, these data confirm the increased incidence of antibiotic resistance in southern Europe [30, 31] . Despite this observation, meropenem retains an essentially unaltered, exceptional and potentially clinically effective antimicrobial spectrum that includes the majority of strains resistant to many other antibiotics.
